Researchers at Vanderbilt University Medical Center plan a Phase 1 clinical trial to evaluate the virus medication Valcyte’s ability to prevent lung tissue scarring in idiopathic pulmonary fibrosis patients. The trial (NCT02871401) will cover 30 IPF patients who have had cytomegalovirus infections. This type of herpes virus causes mononucleosis.
News
Actelion Pharmaceuticals’ Tracleer (bosentan) increased the overall survival and reduced the hospitalizations of patients with pulmonary hypertension stemming from idiopathic pulmonary fibrosis, or IPF-PH, a Japanese clinical trial shows. Researchers published their preliminary findings on the ongoing long-term trial in the journal BMC Pulmonary Medicine. The title of the article…
Phelix Therapeutics has received a $201,665 National Institutes of Health (NIH) grant to continue studying Calpain-based treatments for tissue-scarring diseases like idiopathic pulmonary fibrosis and the liver condition nonalcoholic steatohepatitis. Doctors need better treatments for scarring — or fibrosis — diseases, Phelix said. Current therapies address some of the inflammation that occurs in these…
Cells present in the outer rims of small blood vessels in the lung, called pericytes, convert from a healthy state into a fibrotic one, promoting the progression of pulmonary fibrosis, new findings suggest. The discovery shows how pericytes respond to the microenvironment in the lungs, especially the mechanical changes in…
Looking at pulmonary fibrosis (PF) as an age-related disease and working with a gene therapy that lengthens the life of lung cells, researchers report that they were able to lessen — and even stop — lung fibrosis in mice. “This is the first time that pulmonary fibrosis has been treated as an age-related disease, looking for rejuvenating the affected tissues,” Maria A. Blasco, study's lead author and group leader at the Spanish National Cancer Research Centre (CNIO), in Madrid, said in a press release. The study “Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres” was published in the journal eLife.
A pivotal Phase 3 trial evaluating PBI-4050, a potential treatment of idiopathic pulmonary fibrosis, will be open to all patients with mild-to-moderate IPF regardless of whether they are also taking Ofev (nintedanib) or not, the therapy’s developer, Prometic Life Sciences, announced. The trial, in other words, will evaluate the efficacy and safety of…
A natural compound called gentiopicroside effectively lowers inflammation and tissue scarring in a mouse model of pulmonary fibrosis (PF), say researchers at China’s Kunming Medical University. Since the plant-derived compound targets both fibrotic and inflammatory processes, researchers suggested it may be an ideal drug candidate for lung fibrosis — particularly…
This week marks the launch of the “7,000 Mile Rare Movement,” a nationwide effort to raise money for research into the 7,000 known rare diseases that afflict at least 30 million Americans. The campaign kicks off Feb. 1 and culminates with Rare Disease Day on Feb. 28. Organized by…
Members of an unusual singing group in Bristol, England, are not just having fun, but learning more about their lung diseases. In addition to helping them explore breathing and breathlessness, it’s helping researchers learn about the disorders as well. The group, which includes pulmonary fibrosis patients, is part of a…
Advanced Interactive Response Systems (AIRS), Owlstone Medical and patientMpower are the three winners of the $1 million IPF Catalyst Challenge presented by Three Lakes Partners, a philanthropy organization financing research of idiopathic pulmonary fibrosis (IPF). The three winners will receive $333,333 each to develop their projects. Level Ex received the competition’s Audience…
